
Nariman M. Panahian
Page 1




                                       NARIMAN M. PANAHIAN
                                       PhD, PMP, NPDP, RAC

                                       19011 Gallop Drive
                                       Germantown, MD 20874, USA
                                       240.476.7600 direct
                                       narimanp@comcast.net


SUMMARY:               Nariman is an experienced project director &#173; life scientist, looking for a new leadership role.
                       His areas of expertise include management of complex biotechnology projects, new product
                       development, CMC regulatory affairs and accelerating timelines to new product launch.

               Achievements:
                Diverse new product development, project management, strategy development, CMC and regulatory
                  affairs experience includes therapeutic antibodies, vaccines, MCMs, diagnostic antibodies, small-
                  molecules and neuroprotective drugs
                Reviewer and contributor to The Project Management Body of Knowledge (PMBOK Guide) -Fourth
                  edition- a recognized standard for the project management profession world-wide (in circulation since
                  01/2009).
                Demonstrated ability to integrate corporate strategy with project schedules for deliverables and their
                  Stage-Gate transition towards new product launch
                New product portfolio management, program management, cross-functional team leadership roles in
                  projects within different therapeutic areas: infectious diseases, biodefense, inflammatory, neurology,
                  oncology, pulmonary- COPD and Tuberculosis
                Strong coaching, mentoring and stakeholder management skills with demonstrated ability to lead
                  through a process of growth and change

EXPERIENCE:
1/2012    Director of Project Management
          Managed integrated master-schedule and resource allocations for Aeras' new TB vaccine products
          including pre-clinical R&amp;D, development (IND track), and T.B. vaccines in different phases of clinical
          trials. Used new project management strategies to expedite timelines of cross-functional product
          development teams working on next generation T.B. vaccines with an objective to license and launch a
          next generation T.B. vaccine by 4Q 2015. Multiple therapeutic indications include prophylaxis, treatment,
          use in immuno-compromised individuals (HIV/TB) in developing countries and to prevent transmission
          of T.B. and its virulent forms: MDR-T.B. and XDR-T.B.
                Organized Project Management Office to maximize benefit, better meet stakeholder expectations
                   for deliverables, optimize FTE allocation, better manage and audit projects, support PM
                   methodology, processes and tools
                Rolled out PMO concept within Aeras: trained and mentored Aeras project managers, clinical
                   trial managers, project coordinators; worked in change management and towards transforming
                   Aeras into an integrated enterprise with its South Africa office
                Made PM operations more efficient and effective by alignment with PMI standards
                Optimized schedules of various departments: biostatistics &amp; data management (BDM), R&amp;D,
                   clinical development, technical operations and manufacturing
                Developed project management strategy for timely addressing bottlenecks and constraints with an
                   objective to expedite product delivery timelines and their Stage-Gate transition by 25%
                Standardized risk management, project monitoring and performance reporting
Nariman M. Panahian
Page 2




                         Prioritized novel TB vaccine products within Aeras' portfolio using advanced PM and statistical
                         tools
                         Implemented the concept of new product teams at Aeras and managed new product teams rollout
                         Managed schedules for MVA-85A, Aeras-402 and GSK-M72 next generation clinical vaccine
                         products
                         Worked on multiple project charters, WBS, TPPs, CDPs and iPDPs

01/2011 to     Nariman Panahian Consulting, Germantown, MD, USA
4/2011         Biotechnology consultant
                    Consultant in project management, preclinical Toxicology studies, CMC, VV&amp;T and Regulatory
                      Affairs to private clients
                    Interim R&amp;D director for CEDIS preclinical CRO- a joint venture with Lovelace Respiratory
                      Research Institute (LRRI) to design, construct and commission a GLP compliant, AAALAC
                      accredited facility for preclinical testing of new drugs and vaccines in Europe

04/2010 to     MEDIMMUNE, Gaithersburg, MD, USA
12/10          Contract Project Manager, CMC (Aerotek Scientific, LLC)

                         Led multiple CMC teams under matrix environment, to meet timelines, milestones and corporate
                         commitments. Prepared bi-annual portfolio reviews
                         Responsible for timely implementation of projects' strategic decisions, while minimizing their
                         external costs
                         Managed on-time GMP manufacture of drug substance and drug product, formulation, analytical
                         testing, fill/finish and stability studies
                         Integrated workflows and activities of various CMC Functional Representatives (including
                         PCC&amp;F, Downstream purification, Formulation, Analytical, Quality, Manufacturing, Clinical and
                         Regulatory) in CMC for new therapeutic monoclonal antibodies (anti-RSV-MEDI-557, AE-
                         COPD-MEDI-7814, Lupus-SLE-MEDI-6951 and Pain/Oncology- MEDI-5117)
                         Achieved cycle time reduction, efficiency and process integration in Cycle-1 CMC IND enabling
                         activities. Managed projects' risk, schedules and critical path activities in new product
                         development decreasing projects' timelines by 15% to 30%. Achieved cycle time reduction and
                         efficiency in process integration; participated in company-wide kaizen effort.
                         Advanced user of MS Project Professional and super user of Planisware v.5 and SPSS v15
                         software
                         Submitted Tox Lots to preclinical CROs (Covance and Charles River Reno) for toxicology
                         studies and reviewed reports for IND/CTA/IMPD submission to regulators
                         Responsible for on-time management of clinical material demand (CTM) for IND enabling
                         activities, FTIH, Phase 1 to Phase 2B proof-of-concept studies


10/2004 to     NV-CONSULTING, Germantown, MD, USA
03/2010        Managing Partner
               NVC offered customized management solutions to the Biotechnology sector of the Life Science Industry
                Assisted numerous clients with project and program management needs, implementation of advanced
                  strategy tools, risk assessment, master schedules, resource allocations, statistical interpretations of
                  data, regulatory compliance, product labeling and meeting milestones and corporate commitments
                Managed and synchronized clinical and regulatory timelines
                Reviewed product safety, efficacy, labeling, CMC, quality metrics and VV&amp;T compliance
                Led high complexity projects experiencing significant cost growth and schedule delay
                Reviewed regulatory documents for accuracy and completeness to ensured data quality and integrity
                  Expert knowledge in design controls, CMC, CAPA and QSIT requirements
Nariman M. Panahian
Page 3




                      Experience with environmental monitoring, validations and operation of biological manufacturing
                      facility. Carried out statistical and graphical analysis and presentation of environmental monitoring
                      data, preparation of trending reports and SOPs
                      Performed pathway analyses and statistical interpretations of biomarker data; Identified biomarker
                      profiles linked to serious adverse events and surrogate markers of drug and vaccine efficacy
                      Managed Translational Sciences projects

5/06 to        GLAXOSMITHKLINE BIOLOGICALS, Columbia (MD), King-of-Prussia (PA), Rixensart-Belgium
9/06           Contract Program Manager, Depts. Viral Vaccines &amp; Clinical, Regulatory Affairs and Biodefense
               Services retained for Program management responsibility for Cell and Recombinant Based Influenza
               Vaccine Program, Department of Health and Human Services (HHS) - Biomedical Advanced Research
               and Development Authority (BARDA) $274.75 million award to GSK and ID Biomedical Corporation,
               with the goal to streamline vaccine production in an event of an influenza pandemic (Project BioShield)
                Managed timelines and multidisciplinary teams working in upstream, downstream, scale-up,
                   industrialization, clinical, regulatory and technology transfer activities for manufacture of trivalent
                   and pandemic influenza vaccines within GSK's Strategic Business Unit -Influenza Vaccine Franchise
                Coordinated regulatory and clinical timelines for trivalent, pandemic and monovalent influenza
                   vaccines in accordance with Master Product Development Plan
                Managed timelines for redesign, construction, commissioning and validation for GSK's Marietta (PA)
                   BSL-3 vaccine manufacturing facility
                Prepared integrated, EVMS compliant master schedule and program Gantt files for submission to
                   HHS/BARDA based on industry standards developed by PMI and DAU
                Very good knowledge in infectious disease epidemiology, modes of disease transmission, disease
                   reservoirs and vectors, environmental monitoring, containment and disinfection strategies


6/02 to        MOLECULAR STAGING, INC., New Haven, CT, USA
9/04           Senior Scientist, Project Manager, MSI Clinical Diagnostic Services, Proteomics Discovery Group
                Responsible for designing and leading clinical studies which applied to company's proteomics
                  technology
                Managed processing of patients' samples on ISO 9001 compliant, RCAT cytokine detection high
                  throughput protein robotic microarray platform. This effort led to design and production of
                  Neurological Microarray, identification of biomarkers for inflammatory disease, cancer and sepsis to
                  demonstrate efficacy of new pharmaceuticals
                Successful clinical biomarker validation and cytokine profiles review for drugs and vaccines in
                  different phases of clinical trials using advanced statistical and bioinformatics tools
                Implemented Six-Sigma and Lean methodology for process optimization and product quality control.
                  Boosted number of concurrent projects by 30%, decreased lead time and cycle time for projects
                GLP, CLIA and 21CFR part 11 compliance. Reviewed and prepared technical reports, minutes,
                  executive updates, clients' reports, CMC documentation for IND submission, reviewed and authored
                  QC reports, SOPs, deviations, carried out DOE and statistical process control and biomarker analysis,
                  saving MSI in excess of $500,000
                Led a team of 4 scientists towards successful completion of projects' milestones and strategic goals

9/00 to        INFORMAX, INC., Bethesda, MD, USA
5/02           Biosystems Analyst, Project Manager - Bioinformatics, Department R&amp;D
                Tested and validated second generation VNTI backtranslation tool. VNTI software was a best-seller,
                  sold to more than 30,000 researchers world-wide with interest in microbial and viral DNA and
                  proteins
                Helped launch several new versions of InforMax's flagship software products: VNTI and GenoMax.
                Responsible for an annual budget of $1.1 million
Nariman M. Panahian
Page 4




11/00 to       UNIVERSITY OF ROCHESTER, Rochester, New York
10/01          Adjunct assistant professor, Biochemistry, Biophysics and Neurosciences

7/95 to        UNIVERSITY OF ROCHESTER, Rochester, New York
9/00           Research Assistant Professor, Dept. Biochemistry and Biophysics, Dept. of Neurology, University of
               Rochester Medical Center, Strong Memorial Hospital
                Published &amp; co-authored 11 papers in high impact peer-reviewed journals
                Successful grant writing, numerous approved IACUC protocols, set-up GLP
                American Heart Association grant support for Treatment of stroke with HSVCMVbcl2 and
                  AdCMVHO-1FLAG constructs and determining construct/viral vector immunogenicity
                Reported organ protection by heat shock proteins, small-molecules and heme oxygenase-1 inducer &amp;
                  free radical scavenger -Phenyl-tert-Butyl-Nitrone (-PBN)
                Demonstrated organ protection with small-molecules: glutathione, NO-donors, biliverdin and cGMP
                Described novel protective mechanism for small-molecule methyl-prednisolone in spinal cord injury
                  via activation of glucocorticoid response element of heme oxygenase-2 (HO-2). This finding had
                  great clinical relevance for treatment of spinal cord injury in patients within the 8 hr therapeutic
                  window
                Developed diagnostic antibody staining protocols for Stressgen (available from
                  www.assaydesigns.com)
                Served as a reviewer for Stroke Journal and as a guest reviewer for Neuroscience Letters and JCBF.

               Consulting and New Product Launch experience:
                Ongoing pre-clinical and clinical neuroprotection studies and collaborations with Astra Arcus USA,
                  Sangstat, Neurex (now Elan), ACEA Pharmaceuticals, SRI International, Centaur-Renovis
                Diagnostic antibodies: Stressgen, Inc. (3B8C8- anti-HO1 monoclonal AB, anti-BVR &amp; anti-HO-2
                  polyclonal AB)
                Life support equipment, monitoring equipment, stereomicroscopes and microsurgery: CWE, Inc.,
                  Kramer Scientific, Stoelting and Fine Science Tools (FST)

4/93 to        HARVARD MEDICAL SCHOOL, MASS GENERAL HOSPITAL, Boston, MA
6/95           Senior Postdoctoral Fellow-officer, Neuroscience Center, MGH, Boston, MA
                Demonstrated and published potent protective properties of a new drug, free radical scavenger, small-
                  molecule -PBN
                Reported amelioration of ischemic injury in nNOS gene mutants (Science 1994; 265(5180):1883-5)
                Adapted PowerLab laboratory information management system (LIMs) for on-line data recording,
                  retrieval and analysis
                Demonstrated potent protection against hippocampal experimental injury (e.g. clinical conditions
                  occurring after cardiac arrest, drowning or accidental electrocution) by Retroviral vectors expressing
                  nerve growth factor (MoMLV LN.8RNL NGF(+))
                Implemented improvements to Leica MZ-8 stereo microscope (Kramer Scientific), recommending
                  internal double-barrel coaxial illuminator and plan-apochromatic objective lenses to improve depth-
                  of-perception and surgical distance

1/91 to        STANFORD UNIVERSITY MEDICAL CENTER, Stanford, CA
3/93           Fellow in Neurosurgery, Department of Neurosurgery Stanford University Medical Center
                Leverne K. Purcell scholarship fund recipient for drug discovery and development
                Identified NMDA receptor mediated neuroprotective properties of noncompetitive antagonists of
                   glutamate receptor of two clinical trial drugs: Dextrorphan and Dextromethorphan (sponsor: Hoffman
                   LaRoche, Clinical CNS Research Unit) and competitive antagonist, pre-clinical drug CGS-19755
                   (sponsor: Ciba-Geigy, now Novartis company)
Nariman M. Panahian
Page 5




                      Worked directly with Clinical investigators as a co-investigator, preparing drug development plans
                      and designing toxicology experiments
                      Used novel multivariate statistical approaches for analysis of clinical data
                      Independently operated a 1.5 Tesla GE MRI machine
                      Tested and suggested improvements to prototypes of a mechanically detachable coil for the treatment
                      of aneurysms and occlusion of tumorous blood vessels for Target Therapeutics, Inc.(a division of
                      Boston Scientific Corp; AJNR Am J Neuroradiol. 1994 May;15(5):821-7)

9/89 to        COOPER MEDICAL, INC., DIV. LASER ULTRASONIC, New York, NY
11/90          Scientist &#173; contractor, Neurosurgery Research Labs at the Bellevue Hospital, NYU, NY
                Prototype development, testing and validation of Cooper Ultrasonic Surgical Aspirator/Scalpel
                   (CUSA) for removal of deep seated brain tumors (Cooper Laser-Ultrasonic)
                Evaluated potent calcium channel blocker - immunosuppressant Cyclosporin-A (Sandoz) in
                   experimental spinal cord injury (at NYU)
                Participated in preclinical evaluation of Methyl-Prednisolone, Lazaroid (Tirilazad-Upjohn) in spinal
                   cord injury and statistical interpretation of data for NASCIS clinical trials (at NYU)

12/88 to       UNIVERSITY OF MINNESOTA, Twin Cities, MN
05/89          Honorary Fellow, Department of Cell Biology and Neuroanatomy
                Worked on novel techniques and perfusion solutions to facilitate yield and optimize viability of donor
                  pancreatic islets after their isolation with collagenase
                Developed and formulated chelating solutions and used retrograde organ perfusion technique to
                  isolate donor hepatocytes for allogenic transplantation studies

9/87 to        NATIONAL RESEARCH CENTER OF SURGERY, Moscow, Russia
9/88           Junior Scientist
                Involved in pre-clinical studies of synthetic enkephalins
                Evaluated surgical vascular stapling devices, novel endovascular catheters and tissue adhesives in the
                   clinic
                Attended classes in Chemical and Radiological civilian defense

CITIZENSHIP:

               United States of America

EDUCATION:

               Semashko Moscow Medical Institute, Moscow, Russia
               (Currently one of the Institutes of Moscow Medical Academy "I.M. Sechenov")
               M.D. Qualified as General Physician      Completed With Honors

               Russian State Medical University, Moscow, Russia
               Ph.D., Dept. of Topographical Anatomy, Cell Biology and Experimental Medicine
               Thesis title: "Haemodynamic, structural and functional changes in the liver after intravascular
               administration of islets of Langerhans for the treatment of experimental diabetes."

               Stanford University Medical Center, Stanford, CA
               Diploma, Completion of Postgraduate Medical Studies

               Certifications / Licensures
                Regulatory Affairs Board Certified (RAC &#173; US; January/2010)
Nariman M. Panahian
Page 6




                      New Product Development Professional (NPDP) from Product Development and Management
                      Association (PDMA; October 2008)
                      Project Management Professional (PMP# 315087) from Project Management Institute (PMI, 2005)
                      Certificates in Radiation protection program training: sources and control of ionizing radiation,
                      exposure control, safe handling of radioactive material, personnel monitoring, surveys and radioactive
                      waste management, University of Minnesota, 03/13/1989 additional courses taken at the University of
                      Rochester, in 1995 and 1997, certified user of Seintl radiation monitors and dosimeters.


SOCIETY MEMBERSHIP:
           Regulatory Affairs Professional Society (RAPS)
           PMIWDC chapter
           Product Development and Management Association (PDMA)
           Project Management Institute (PMI)

GRANT SUPPORT / AWARDS:
           American Heart Association Grant-in-Aid award recipient (#960162 1996-1999): "Hypoxia
            responsive gene therapy in the treatment of focal cerebral ischemia"
           Training Grant in Geriatrics and Neurobiology of Aging (NIA T32 AG00107-13 1995-1997)
           Lucille P. Markey Charitable Trust Award (#91-24 1996-1997)
           Dean's Fellowship award (# 1HAA 234 94799) in pharmacology and electrophysiology of preclinical
            neuroprotection in stroke
           Leverne Purcell Foundation Award, Stanford University Medical Center (1991-1993)

PEER-REVIEWED JOURNAL ARTICLES:
           Twenty five Peer-reviewed papers, brief communications and editorial comments published (listed in
            Medline and related databases)
           Publications in Russian: Panahian N, Zhidkov IL, Ostroverkhov GE, Maliugin EF (1986) Liver
            haemodynamics after intravascular transplantation of the pancreatic islets. VINITI N8332-B-86.

PUBLISHED BOOK CHAPTERS:
           Panahian N: Models of focal brain ischemia. In: Current Protocols in Toxicology eds. Costa L, Reed DJ,
           et al., Wiley, (Published November, 2000), Supplement 6, pp. 11.9.1-11.9.26.

               Panahian N: Models of global cerebral ischemia: Current Protocols in Toxicology eds. Costa L., Reed
               D.J., et al., Wiley, (Published, August, 2000), Supplement 5, pp.11.8.1 -11.8.24.

               Mahin Maines &amp; Nariman Panahian: The heme oxygenase system and cellular defense mechanisms.
               Hypoxia from genes to the bedside (Published January 31, 2002) Roach RC, Wagner PD, Hackett PH eds.
               Advances in Experimental Medicine and Biology Vol.502, Chapter 17, p.249-272. ISBN-10: 0306466961


               01Apr12



  
    21CFR part 11
  
  
    streamline
  
  
    budget
  
  
    bi
  
  
    change management
  
  
    com
  
  
    competitive
  
  
    concept
  
  
    Consultant
    Consulting
  
  
    clients
  
  
    data management
  
  
    delivery
  
  
    Department of Health
  
  
    designing
  
  
    Product Development
    product
          development
  
  
    documentation
  
  
    Downstream
    downstream
  
  
    forms
  
  
    Functional
    functional
  
  
    GLP
  
  
    GMP
  
  
    grant writing
  
  
    hr
  
  
    IND
  
  
    interpretation
  
  
    ISO 9001
  
  
    Laser
  
  
    Letters
  
  
    laboratory information management system
    LIMs
  
  
    Office
    office
  
  
    MS Project
  
  
    window
  
  
    MSI
  
  
    enterprise
  
  
    new product
                         development
  
  
    next
  
  
    novel
  
  
    optimization
  
  
    pathway
  
  
    processes
  
  
    Program management
    program management
  
  
    Project Management
    project management
  
  
    protocols
  
  
    Quality
    quality
  
  
    quality control
  
  
    recording
  
  
    reporting
  
  
    Research
  
  
    risk assessment
  
  
    risk management
  
  
    robotic
  
  
    safety
  
  
    Scientific
  
  
    Six-Sigma
  
  
    SPSS v
  
  
    statistical process control
  
  
    strategy
    Strategic
    strategic
  
  
    time management
  
  
    transmission
  
  
    upstream
  
  
    validation
  


